Richard Muwonge
Overview
Explore the profile of Richard Muwonge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
3045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sangrajrang S, Pitakkarnkul S, Muwonge R, Ploysawang P, Pangmuang P, Seeda K, et al.
Asian Pac J Cancer Prev
. 2023 Aug;
24(8):2615-2619.
PMID: 37642046
Background: We determined testing of self-sampling vagina swabs for Human Papilloma Virus (HPV) can be used to screen for cervical disease in outpatient clinics. Methods: In this study, women attending...
12.
13.
Lucas E, Murillo R, Arrossi S, Barcena M, Chami Y, Nessa A, et al.
Elife
. 2023 May;
12.
PMID: 37191660
It is quite well documented that the COVID-19 pandemic disrupted cancer screening services in all countries, irrespective of their resources and healthcare settings. While quantitative estimates on reduction in volume...
14.
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al.
Vaccine
. 2022 Nov;
41(1):236-245.
PMID: 36446654
Background: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income...
15.
Gheit T, Muwonge R, Lucas E, Galati L, Anantharaman D, McKay-Chopin S, et al.
Oral Oncol
. 2022 Nov;
136:106244.
PMID: 36402055
Background: Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Although the efficacy of the HPV vaccine in preventing the development of cervical pre-malignant lesions has...
16.
Ramadas K, Basu P, Mathew B, Muwonge R, Venugopal M, Prakasan A, et al.
Cancer
. 2022 Nov;
129(2):272-282.
PMID: 36321193
Background: This study presents the preliminary results of a randomized controlled trial (RCT) initiated in January 2006 in India to evaluate the effectiveness of clinical breast examination (CBE) in reducing...
17.
Man I, Georges D, M de Carvalho T, Saraswati L, Bhandari P, Kataria I, et al.
Lancet Oncol
. 2022 Sep;
23(11):1419-1429.
PMID: 36174583
Background: Despite the high burden of cervical cancer, access to preventive measures remains low in India. A single-dose immunisation schedule could facilitate the scale-up of human papillomavirus (HPV) vaccination, contributing...
18.
Baisley K, Kemp T, Kreimer A, Basu P, Changalucha J, Hildesheim A, et al.
Lancet Glob Health
. 2022 Sep;
10(10):e1485-e1493.
PMID: 36113532
Background: Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9-14 years, or as three doses in older individuals. We compared antibody responses after one dose...
19.
Mosquera I, Ilbawi A, Muwonge R, Basu P, Carvalho A
Lancet Glob Health
. 2022 Sep;
10(10):e1443-e1452.
PMID: 36113529
Background: Information on cancer statistics and cancer control policies is limited in fragile states. This paper describes the cancer burden and status of cancer control measures in these countries. Methods:...
20.
Smelov V, Trusova O, Barbier S, Muwonge R, Grankov V, Rusovich V, et al.
Int J Environ Res Public Health
. 2022 Jul;
19(14).
PMID: 35886558
In Belarus and several EECA countries, periodic population-based chest X-ray "fluorography programme" use as a mass screening tool for the diagnosis of tuberculosis (TB) has been used for decades. This...